A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Inclusion Criteria: * Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy; or relapsed or refractory Non-Hodgkin lymphoma for whom no standard therapy is available.. * Adequate Bone Marrow Function. * Adequate Renal \& Liver Function. * Adequate Performance Status Exclusion Criteria: * Patients with known symptomatic CNS metastases or lepotomeningeal disease requiring steroids. * Previous high-dose chemotherapy requiring allogenic stem cell rescue. * Prior treatment with a CD47 or signal regulatory protein (SIRP) alpha targeting agent.